Global Trends in the Medical Device Industry and Supply Chain



MPO Summit Interlocken, Colorado October 11, 2018



Tony Freeman



About A.S. Freeman Advisors

- Merger and acquisition advisory services
- Corporate strategy in support of transactions
- Focus on precision manufacturing and specialty materials markets
- Publishes Global Trends: Medical Device and Diagnostic OEM Strategy and Implications for the Supply Chain

Perspective

- A focus on the large scale trends, the "tectonic forces" driving the device industry
 - Device manufacturers (OEMs)
 - Supply chain companies
- Looking out three to ten years
- One lens reveals most of what is going on in the device market *risk transfer*



Economic Risk Defined

- Not everyday risk = danger
- Economic risk = Uncertainty with opportunities for loss or gain
- In the medical device world, roles are shifting in response to new incentives and penalties
- The ability to manage through risk transfers will make or break companies in the device industry



What keeps Device OEM CEOs up at 3AM?

- Two obvious issues
 - Favorable demographics
 - Growth of healthcare in developing countries
- We'll focus on significant but less discussed risks
 - Changing reimbursement strategies in their most lucrative market
 - Fewer, more powerful customers
- Three responses to risk from device manufacturing specifics
 - Consolidation via M&A
 - Move from individual devices to complete care systems
 - Digitization



Source: Organization for Economic Co-operation and Development, OECD 2018 Healthcare Database, https://stats.oecd.org/index.aspx?DataSetCode=HEALTH_STAT

America First

- The United States the largest and richest markets for devices in the world
- US spends 18% of GDP on healthcare ¹
- May rise to over 20% by 2022
- The United States represents 40% of the global device market ²
- Through rich reimbursements the US subsidizes device development for the rest of the world
- Devices must be designed to succeed in the US market, under US market conditions



What is Value-Based Reimbursement?

Risk #1: Value Based Reimbursement (VBR)

Let's start with what it isn't

- We all grew up with fee-for-service
- Economically, this fee-for-service rewards activity ... not outcomes
- As the US healthcare spending crossed 15% of GDP, major payers looked for new approaches

VBR rewards physicians and hospitals for superior outcomes

- Several forms of VBR but most common is "bundled payment"
- Healthcare provider receives a single payment for all services and products
- Complications, readmittances, extra follow-ups, longer therapies all on the provider
- Creates incentives for effective medicine



Rise of Value Based Reimbursement (VBR)

- VBR were 23% of reimbursements in 2016, projected to rise to 50% by 2020 ³
- *Risk is transferring rapidly from payers to providers and physicians*



■ VBR Payments %



VBR Impact on Device World

- In a VBR world, if one device outperforms another, physicians and providers have economic incentives for using the superior device
- OEMs are increasingly going to market stressing outcome and economic benefits of their products
- Less capable devices are dropped from order lists
- Risk is shifting from providers/physicians to OEMs
- That risk shift is showing up in OEM strategies
- OEMs are accepting the risk, reinforcing where in markets where they can win and retreating in those they where they will lose





Risk #2: Fewer, More Powerful Customers

The days of independent hospitals in the US are over

- 68% of American hospitals are systemaffiliated, up from 51% in 1999 ⁴
- No more purchasing departments, sophisticated buying groups
- Other nations have relied on centralized purchasing to some degree

Community System-Affiliated vs. I

3198

66%





Fewer, More Powerful Customers

The days of the independent physician are numbered

- Over 67% work for hospitals or corporate practices ⁵
- Fewer points of sale in corporate or hospital-affiliated practices
- Buying power is concentrated, shifting risk from provider and physician to the OEM

Physicians in US



- Independent
- Employed or Corporate Practice



Medtronic – Covidien BD – Carefusion

J&J discarding and drawing

Response #1: Consolidation of Large OEMs via M&A

- Large OEMs have turned to M&A to acquire strong positions in specific areas of care
- Similarly, non-strategic units are shed
- Adjusting risk in a changing world

Selected list of major M&A transactions of last 4 years

Acquirer	Target	Deal Size (\$B)	Year
Company	Target		
Abbott	St. Jude	\$25	2017
Becton Dickinson	CR Bard	\$24	2017
Canon	Toshiba Medical	\$6	2016
Medtronic	Covidien	\$43	2015
Becton Dickinson	Carefusion	\$12	2015
Danaher	Pall	\$12	2015
Zimmer	Biomet	\$13	2015
Fortive	J&J Sterilization	\$2	2018
Company	Company		
J&J	Abbott Medical Optics	\$4.3	2017
Cardinal Health	Medtronic patient recovery and monitoring	\$6.1	2017
Integra Lifesciences	J&J Codman Neuro	\$1	2017
Platinum Equity	J&J LifeScan	\$2.4	2017
Medtronic	S&N gynecology	\$0.35	2016
Cardinal Health	J&J Cordis	\$2	2015





Response #2: From Devices to Care Systems

- Rarely can a single device redefine a level of care. A move from standalone products to product families
- Product families to product/service packages
- Taking over hospital departments and sometimes, hospitals
 - Fresenius
 - Medtronic ORMS
 - Strkyer Endo "Operating Room of the Future"
- At its most extreme example, a hospital becomes a healthcare mall, a real estate and marketing business with care outsourced.
 - OEMs taking over care to accept outcome risk



Response #3: New Classes of Digital Devices & Ecosystems

- For all the magnificent technology in medical devices they are among the last devices to become digitally aware
- Devices are increasingly becoming single points in a digital ecosystem
- Better results through shared information and analytics

Two quick examples \rightarrow



3M Intelligent Control Inhaler

- **1956** First mechanical inhaler
- **1993** First breath controlled inhaler
- 2016 "Smart Inhaler"

- Reminds patient to take medicine
- Always delivers correct dosage, regardless of breath
- Records results, shares with patient and providers via phone or tablet
- Primary application: asthma medication

The most common cause of asthma ER visits is failure to take medication regularly and properly

Better Outcomes Through Digitization

Scope of asthma problem in US⁶:

- Average hospital stay of 3.6 days for 439,000 hospitalizations/year
- 1.8 million ER visits per year
- 14.2 million physician visits
- Estimated cost of over \$50 billion per year in direct and indirect costs for asthma care







Wright Medical Tornier Aequalis Digital Ecosystem

Wright Medical's packaging of BLUEPRINT[™] Planning Software and Aequalis Perform+[™] Shoulder System

Not just products – a treatment system:

- BLUEPRINT surgical planning software
- Communications software to the OR
- Positioning and navigation functions for shoulder surgeries
- Wright Tornier Aequalis shoulders and instruments

A digital infrastructure in support of a surgical procedure TAKEWAY: Competitive advantage over traditional shoulder surgery products -offering products in a <u>connected system</u> yields superior results

Wright Tornier Results

A surgeon can:

- Pre-plan and do a dry run of the surgery on a computer screen in their office, complete with 3D visualization
- Transmit the procedure plan to the OR and other members of the surgical team
- Use the plan to properly align instruments and implants during the surgery

Results:

- Superior alignment
- Better placement in bone
- Fewer complications and readmissions







How About the Supply Chain?

- OEMs transferring manufacturing risk to supply chain
- Everything can be outsourced but to whom?
- From the OEMs perspective better to have larger, more stable suppliers risk is more effectively mitigated
- "One neck to choke"
- Rise of the global CMs in the device space
- Strategies for managing manufacturing transference risk







Rise of the Global CMs

- 8 of 10 largest medical contract manufacturers are global CMs with roots in electronics manufacturing
- Willing to take on the risks of greater LCC sourcing
- Used to gross margins in high single/low double digits









Rise of the Global CMs – J&J and Jabil

- On August 2 Johnson & Johnson announced progress on its restructuring of the Medical Devices business unit ⁷:
 - RIF 5% of workforce (2,600 jobs)
 - It had formed a strategic collaboration with Jabil to produce a range of products for DePuy/Synthes and Ethicon Endo
- J&J projects savings between \$600 and \$800 million annually by 2022
- On September 25 Jabil announced it would take over 14 J&J sites as part of the strategic collaboration ⁸
- J&J transferring manufacturing and facility risk to Jabil
- Jabil's 2017 gross margin was 8.1% ⁹



Four Rules for Prospering

- Unique knowledge
- Speed to market
- Right the first time is a requirement
- Ability to support digital devices
 - Electronics
 - Software
 - Systems



Tony Freeman A.S. Freeman

For More Information

Tony Freeman President A. S. Freeman Advisors

<u>tfreeman@asfreeman.com</u> (917) 868-0772

References

- 1. <u>https://stats.oecd.org/index.aspx?DataSetCode=HEALTH_STAT_</u>Organization for Economic Co-operation and Development, OECD 2018 Healthcare Database. Downloadable dataset.
- 2. <u>https://www.selectusa.gov/medical-technology-industry-united-states</u>. In 2017 approximately 40% of global device sales are in the United States, the world's largest market. Source is International Trade Administration of the Department of Commerce.
- 3. <u>https://www.healthaffairs.org/do/10.1377/hblog20160708.055764/full/</u>Health Affairs, *Value Based Reimbursement: The Rock Thrown Into The Health Care Pond*, Bruce Merlin Fried, Jeremy David Sherer, July 8, 2016
- 4. <u>https://aharesourcecenter.wordpress.com/2017/01/25/number-of-system-affiliated-vs-independent-community-hospitals-1999-2015/</u> American Hospital Association 2016 statistics.
- 5. <u>https://www.accenture.com/t20150608T044420_w_/us-</u> en/_acnmedia/Accenture/ConversionAssets/DotCom/Documents/Global/PDF/Dualpub_15/Accenture-The-Doctor-Will-Not-See-You.pdf Accenture, Inc. 2015 statistics.
- 6. <u>https://www.cdc.gov/asthma/impacts_nation/asthmafactsheet.pdf</u> U. S. Centers for Disease Control
- 7. <u>https://www.sec.gov/Archives/edgar/data/200406/000020040618000041/a2q10q07-01x18.htm</u> Johnson & Johnson Form 10-Q for second quarter, 2018. Please see Note 12 Restructuring.
- 8. <u>https://evertiq.com/news/44859</u> Jabil to take over 14 J&J sites.
- 9. <u>https://www.sec.gov/Archives/edgar/data/898293/000119312517313834/d424121d10k.htm#tx424121_8</u> Jabil Inc. FY2017 Form 10-K